NkartaÂ Inc (NKTX)

Name: NkartaÂ Inc (NKTX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: NkartaÂ Inc (NKTX)

Stock Card

$2.77

$0.07 (2.41%)

As on 02-Sep-2026 16:00EDT

Market cap

$198 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

0.8

Div. Yield

0 %

NkartaÂ Inc (NKTX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 2.66 High: 2.83

52 Week Range

Low: 1.70 High: 3.72

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.4 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

0.9
Debt to Equity

0
Book Value

$--
EPS

$-1.6
Face value

--
Shares outstanding

71,624,791

6 Years Aggregate

CFO

$-278.14 Mln

EBITDA

$-438.53 Mln

Net Profit

$-394.44 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
NkartaÂ Inc (NKTX)	49.5	32.3	-11.9	30.4	16.0	-38.9	--
BSE Sensex	-9.6	-2.0	3.1	-4.7	5.4	6.0	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 02-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021
NkartaÂ Inc (NKTX)	-25.7	-62.0	10.2	-61.0	-75.0
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3
BSE Sensex	9.1	8.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
NkartaÂ Inc (NKTX)	2.8	197.7	0.0	-117.3	--	-41.9	--	0.8
Arrowhead Pharmaceuticals (ARWR)	85.4	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Cytokinetics Inc (CYTK)	71.9	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	58.5	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	109.7	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	369.2	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	546.9	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	593.0	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	357.5	9,625.4	0.0	-339.1	--	-30.6	--	7.6
Protagonist Therapeutics (PTGX)	146.1	9,339.4	282.0	82.9	-28.6	11.4	140.1	11.5

Shareholding Pattern

View Details

About NkartaÂ Inc (NKTX)

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK)... targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California. Read more

CEO, President & Director

Mr. Paul J. Hastings
CEO, President & Director

Mr. Paul J. Hastings
Headquarters

South San Francisco, CA
Website

https://www.nkartatx.com

FAQs for NkartaÂ Inc (NKTX)

What is the current share price of NkartaÂ Inc (NKTX) Today?

The share price of NkartaÂ Inc (NKTX) is $2.77 (NASDAQ) as of 02-Sep-2026 16:00 EDT. NkartaÂ Inc (NKTX) has given a return of 16.03% in the last 3 years.

What is the current PB & PE ratio of NkartaÂ Inc (NKTX)?

Since, TTM earnings of NkartaÂ Inc (NKTX) is negative, P/E ratio is not available.
The P/B ratio of NkartaÂ Inc (NKTX) is 0.80 times as on 28-Aug-2026, a 85 discount to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.